Javascript must be enabled to continue!
Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients
View through CrossRef
Abstract
Background
Cardiovascular (CV) disease is the leading cause of mortality in patients with end-stage kidney disease (ESKD). The aim of the present study was to determine whether Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) could be an independent predictor of CV events and all-cause mortality in black African haemodialysis patients.
Methods
We carried out a prospective cohort study of all consecutive hemodialysis (HD) patients between August 2016 and July 2020, admitted in six hemodialysis centers of Kinshasa, Democratic Republic of Congo. Independent determinants of plasma PCSK-9 measured by ELISA were sought using multiple linear regression analysis. Kaplan-Meier’s method described the incidence of CV events while competitive and proportional risk models looked for independent risk factors for death at the .05 significance level.
Results
Out of 207 HD patients, 91 (43.9%) died; 116 (56.1%) have survived. PCSK9 level was significantly higher in deceased patients compared to survivors: 28.0 (24.0–31.0) ng/l vs 9.6 (8.6–11.6) ng/ml (p < 0.001). Patients with plasma PCSK9 levels in tertile 3 had a higher incidence of CV events and mortality compared to patients with plasma PCSK9 levels in tertile 2 or tertile 1 (p < 0.001). Tertile 3 negatively influence survival rates (26.6%) compared to tertile 2 (54.7%) and tertile 1 (85.3%). Patients in tertile 3 and tertile 2 had a 4-fold higher risk of death than patients in tertile 1. After adjustment for all parameters, competitive risk analysis showed that mortality was 2 times higher in patients with stroke. Similarly, serum albumin < 3.5 g/dL or PCSK9 in tertile 3 were respectively associated with 2 or 6 times higher rates of deaths.
Conclusion
Elevated plasma PCSK9 level is an independent major predictor of incident CV events and all-cause mortality in black African HD patients.
Springer Science and Business Media LLC
Title: Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients
Description:
Abstract
Background
Cardiovascular (CV) disease is the leading cause of mortality in patients with end-stage kidney disease (ESKD).
The aim of the present study was to determine whether Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) could be an independent predictor of CV events and all-cause mortality in black African haemodialysis patients.
Methods
We carried out a prospective cohort study of all consecutive hemodialysis (HD) patients between August 2016 and July 2020, admitted in six hemodialysis centers of Kinshasa, Democratic Republic of Congo.
Independent determinants of plasma PCSK-9 measured by ELISA were sought using multiple linear regression analysis.
Kaplan-Meier’s method described the incidence of CV events while competitive and proportional risk models looked for independent risk factors for death at the .
05 significance level.
Results
Out of 207 HD patients, 91 (43.
9%) died; 116 (56.
1%) have survived.
PCSK9 level was significantly higher in deceased patients compared to survivors: 28.
0 (24.
0–31.
0) ng/l vs 9.
6 (8.
6–11.
6) ng/ml (p < 0.
001).
Patients with plasma PCSK9 levels in tertile 3 had a higher incidence of CV events and mortality compared to patients with plasma PCSK9 levels in tertile 2 or tertile 1 (p < 0.
001).
Tertile 3 negatively influence survival rates (26.
6%) compared to tertile 2 (54.
7%) and tertile 1 (85.
3%).
Patients in tertile 3 and tertile 2 had a 4-fold higher risk of death than patients in tertile 1.
After adjustment for all parameters, competitive risk analysis showed that mortality was 2 times higher in patients with stroke.
Similarly, serum albumin < 3.
5 g/dL or PCSK9 in tertile 3 were respectively associated with 2 or 6 times higher rates of deaths.
Conclusion
Elevated plasma PCSK9 level is an independent major predictor of incident CV events and all-cause mortality in black African HD patients.
Related Results
Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia
Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia
Abstract
Aims
Familial hypercholesterolemia patients are characterized by early onset of coronary artery calcification and ather...
On Flores Island, do "ape-men" still exist? https://www.sapiens.org/biology/flores-island-ape-men/
On Flores Island, do "ape-men" still exist? https://www.sapiens.org/biology/flores-island-ape-men/
<span style="font-size:11pt"><span style="background:#f9f9f4"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><spa...
Selection of a Single Chain Variable Fragment Antibody (scFv) against Subtilisin BRC and its Interaction with Subtilisin BRC
Selection of a Single Chain Variable Fragment Antibody (scFv) against Subtilisin BRC and its Interaction with Subtilisin BRC
Background:
The focus of this study was the selection of a single chain variable fragment
antibody (scFv) against subtilisin BRC, a fibrinolytic enzyme using phage display, and to...
Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis
Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis
Background: A large amount of evidence suggests that proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors have clinical benefits in patients with cardiovascular disease...
PCSK9 Inhibitors: Pharmacology and Therapeutic Potential
PCSK9 Inhibitors: Pharmacology and Therapeutic Potential
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is a proteolytic enzyme that indirectly regulates serum LDL cholesterol by destroying LDL receptors. In clinical studies, the ...
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Abstract
Aims
Proprotein convertase subtilisin/kexin type-9 (PCSK9), a molecular determinant of low-density lipoprotein (LDL) re...
MO823EARLY MORTALITY IN INCIDENT HEMODIALYSIS PATIENTS
MO823EARLY MORTALITY IN INCIDENT HEMODIALYSIS PATIENTS
Abstract
Background and Aims
Chronic kidney disease (CKD) is known to have significant morbi-mortality worldwide. Patients with ...
Diversification of metazoan Kexin-like proprotein convertases: insights from the leech
Helobdella
Diversification of metazoan Kexin-like proprotein convertases: insights from the leech
Helobdella
Abstract
Intercellular communication is quintessential for multicellularity and often mediated by secreted peptide ligands. In Metazoa, proprotei...

